Fetal Drug Therapy

Clinical Pharmacology During Pregnancy

Volumn , Issue , 2013, Pages 55-72

  Rytting, Erik ^a   Ahmed, Mahmoud S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882652172     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386007-1.00005-2     Document Type: Chapter

References (105)

1. Adzick N.S., Thom E.A., Spong C.Y., Brock J.W., Burrows P.K., Johnson M.P., et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011, 364:993-1004.
2. Miller R.K. Fetal drug therapy: principles and issues. Clin Obstet Gynecol 1991, 34:241-250.
3. Kohl T. Minimally invasive fetoscopic interventions: an overview in 2010. Surg Endosc 2010, 24:2056-2067.
4. Evans M.I., Pryde P.G., Reichler A., Bardicef M., Johnson M.P. Fetal drug therapy. West J Med 1993, 159:325-332.
5. Roberts D., Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006, CD004454.
6. Rosenberg A.A., Galan H.L. Fetal drug therapy. Pediatr Clin North Am 1997, 44:113-135.
7. Api O., Carvalho J.S. Fetal dysrhythmias. Best Pract Res Clin Obstet Gynaecol 2008, 22:31-48.
8. Yankowitz J., Weiner C. Medical fetal therapy. Baillieres Clin Obstet Gynaecol 1995, 9:553-570.
9. Kleinman C.S., Nehgme R.A. Cardiac arrhythmias in the human fetus. Pediatr Cardiol 2004, 25:234-251.
10. Ward R.M. Pharmacology of the maternal-placental-fetal-unit and fetal therapy. Prog Pediatr Cardiol 1996, 5:79-89.
11. Nimkarn S., New M.I. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a paradigm for prenatal diagnosis and treatment. Ann N Y Acad Sci 2010, 1192:5-11.
12. Devaney S.A., Palomaki G.E., Scott J.A., Bianchi D.W. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011, 306:627-636.
13. Rijnders R.J., Christiaens G.C., Bossers B., van der Smagt J.J., van der Schoot C.E., de Haas M. Clinical applications of cell-free fetal DNA from maternal plasma. Obstet Gynecol 2004, 103:157-164.
14. Merce Fernandez-Balsells M., Muthusamy K., Smushkin G., Lampropulos J.F., Elamin M.B., Abu Elnour N.O., et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010, 73:436-444.
15. Bliddal S., Rasmussen A.K., Sundberg K., Brocks V., Skovbo P., Feldt-Rasmussen U. Graves' disease in two pregnancies complicated by fetal goitrous hypothyroidism: successful in utero treatment with levothyroxine. Thyroid 2011, 21:75-81.
16. van den Akker E.S., Oepkes D. Fetal and neonatal alloimmune thrombocytopenia. Best Pract Res Clin Obstet Gynaecol 2008, 22:3-14.
17. Illanes S., Soothill P. Noninvasive approach for the management of hemolytic disease of the fetus. Expert Rev Hematol 2009, 2:577-582.
18. Moise K.J. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008, 13:207-214.
19. Harman C.R. Amniotic fluid abnormalities. Semin Perinatol 2008, 32:288-294.
20. von Dadelszen P., Dwinnell S., Magee L.A., Carleton B.C., Gruslin A., Lee B., et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011, 118:624-628.
21. Hui L., Challis D. Diagnosis and management of fetal growth restriction: the role of fetal therapy. Best Pract Res Clin Obstet Gynaecol 2008, 22:139-158.
22. Nygaard U., Sundberg K., Nielsen H.S., Hertel S., Jorgensen C. New treatment of early fetal chylothorax. Obstet Gynecol 2007, 109:1088-1092.
23. Yang Y.S., Ma G.C., Shih J.C., Chen C.P., Chou C.H., Yeh K.T., et al. Experimental treatment of bilateral fetal chylothorax using in utero pleurodesis. Ultrasound Obstet Gynecol 2012, 39:56-62.
24. Anandakumar C., Biswas A., Wong Y.C., Chia D., Annapoorna V., Arulkumaran S., et al. Management of non-immune hydrops: 8 years' experience. Ultrasound Obstet Gynecol 1996, 8:196-200.
25. Randenberg A.L. Nonimmune hydrops fetalis part I: etiology and pathophysiology. Neonatal Netw 2010, 29:281-295.
26. Sebire N.J., Jauniaux E. Fetal and placental malignancies: prenatal diagnosis and management. Ultrasound Obstet Gynecol 2009, 33:235-244.
27. Rayburn W.F. Fetal drug therapy: an overview of selected conditions. Obstet Gynecol Surv 1992, 47:1-9.
28. Siegfried N., van der M.L., Brocklehurst P., Sint T.T. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011, CD003510.
29. Vahakangas K., Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009, 158:665-678.
30. Prouillac C., Lecoeur S. The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab Dispos 2010, 38:1623-1635.
31. Ganapathy V., Prasad P.D., Ganapathy M.E., Leibach F.H. Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 2000, 294:413-420.
32. Young A.M., Allen C.E., Audus K.L. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003, 55:125-132.
33. Pasanen M., Pelkonen O. The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol 1994, 24:211-229.
34. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv Drug Deliv Rev 1999, 38:81-97.
35. Nanovskaya T.N., Deshmukh S.V., Nekhayeva I.A., Zharikova O.L., Hankins G.D., Ahmed M.S. Methadone metabolism by human placenta. Biochem Pharmacol 2004, 68:583-591.
36. Deshmukh S.V., Nanovskaya T.N., Hankins G.D., Ahmed M.S. N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol 2004, 67:885-892.
37. Deshmukh S.V., Nanovskaya T.N., Ahmed M.S. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther 2003, 306:1099-1105.
38. Hakkola J., Pasanen M., Hukkanen J., Pelkonen O., Maenpaa J., Edwards R.J., et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 1996, 51:403-411.
39. Hakkola J., Raunio H., Purkunen R., Pelkonen O., Saarikoski S., Cresteil T., et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996, 52:379-383.
40. Nanovskaya T.N., Nekhayeva I.A., Hankins G.D., Ahmed M.S. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008, 198. 126-124.
41. Hemauer S.J., Patrikeeva S.L., Nanovskaya T.N., Hankins G.D., Ahmed M.S. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem Pharmacol 2009, 78:1272-1278.
42. Fan S.Z., Susetio L., Tsai M.C. Neuromuscular blockade of the fetus with pancuronium or pipecuronium for intra-uterine procedures. Anaesthesia 1994, 49:284-286.
43. David A.L., Peebles D. Gene therapy for the fetus: is there a future?. Best Pract Res Clin Obstet Gynaecol 2008, 22:203-218.
44. Davey M.G., Flake A.W. Genetic therapy for the fetus: a once in a lifetime opportunity. Hum Gene Ther 2011, 22:383-385.
45. Pschera H. Current status in intrauterine fetal stem cell therapy. J Obstet Gynaecol Res 1998, 24:419-424.
46. Tiblad E., Westgren M. Fetal stem-cell transplantation. Best Pract Res Clin Obstet Gynaecol 2008, 22:189-201.
47. Shaw S.W., David A.L., De Coppi P. Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid. Curr Opin Obstet Gynecol 2011, 23:109-116.
48. Mehta V., Abi N.K., Waddington S., David A.L. Organ targeted prenatal gene therapy - how far are we?. Prenat Diagn 2011, 31:720-734.
49. Rytting E., Nguyen J., Wang X., Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv 2008, 5:629-639.
50. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010, 62:1052-1063.
51. Bajoria R., Fisk N.M., Contractor S.F. Liposomal thyroxine: a noninvasive model for transplacental fetal therapy. J Clin Endocrinol Metab 1997, 82:3271-3277.
52. Myllynen P.K., Loughran M.J., Howard C.V., Sormunen R., Walsh A.A., Vahakangas K.H. Kinetics of gold nanoparticles in the human placenta. Reprod Toxicol 2008, 26:130-137.
53. Menjoge A.R., Rinderknecht A.L., Navath R.S., Faridnia M., Kim C.J., Romero R., et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J Control Release 2011, 150:326-338.
54. Wick P., Malek A., Manser P., Meili D., Maeder-Althaus X., Diener L., et al. Barrier capacity of human placenta for nanosized materials. Environ Health Perspect 2010, 118:432-436.
55. Saunders M. Transplacental transport of nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:671-684.
56. Menezes V., Malek A., Keelan J.A. Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure. Curr Pharm Biotechnol 2011, 12:731-742.
57. Coke G.A., Baschat A.A., Mighty H.E., Malinow A.M. Maternal cardiac arrest associated with attempted fetal injection of potassium chloride. Int J Obstet Anesth 2004, 13:287-290.
58. Noble R., Rodeck C.H. Ethical considerations of fetal therapy. Best Pract Res Clin Obstet Gynaecol 2008, 22:219-231.
59. Sastry B.V. Techniques to study human placental transport. Adv Drug Deliv Rev 1999, 38:17-39.
60. Weiss L. Cell and Tissue Biology: A Textbook of Histology 1988, Urban & Schwarzenberg, Baltimore. 6th ed.
61. Baergen R.N. Overview and microscopic survey of the placenta. Manual of Pathology of the Human Placenta 2011, 85-108. Springer, New York. R.N. Baergen (Ed.).
62. Ernst L.M. Placenta. Color Atlas of Fetal and Neonatal Histology 2011, 363-388. Springer, New York. L.M. Ernst, E.D. Ruchelli, D.S. Huff (Eds.).
63. Huppertz B. The anatomy of the normal placenta. J Clin Pathol 2008, 61:1296-1302.
64. Castellucci M., Kaufmann P. Basic structure of the villous trees. Pathology of the Human Placenta 2006, 50-120. Springer, New York. K. Benirschke, P. Kaufmann, R.N. Baergen (Eds.).
65. Moe A.J. Placental amino acid transport. Am J Physiol 1995, 268:C1321-C1331.
66. Jaeggi E.T., Tulzer G. Pharmacological and interventional fetal cardiovascular treatment. Paediatric Cardiology 2010, 199-218. Churchill Livingstone/Elsevier, Philadelphia. R. Anderson, E. Baker, A. Redington, M. Rigby, D. Penny, G. Wernovsky (Eds.).
67. Nagashima M., Asai T., Suzuki C., Matsushima M., Ogawa A. Intrauterine supraventricular tachyarrhythmias and transplacental digitalisation. Arch Dis Child 1986, 61:996-1000.
68. Azancot-Benisty A., Jacqz-Aigrain E., Guirgis N.M., Decrepy A., Oury J.F., Blot P. Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias. J Pediatr 1992, 121:608-613.
69. Younis J.S., Granat M. Insufficient transplacental digoxin transfer in severe hydrops fetalis. Am J Obstet Gynecol 1987, 157:1268-1269.
70. Weiner C.P., Thompson M.I. Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. Am J Obstet Gynecol 1988, 158:570-573.
71. Wiggins J.W., Bowes W., Clewell W., Manco-Johnson M., Manchester D., Johnson R., et al. Echocardiographic diagnosis and intravenous digoxin management of fetal tachyarrhythmias and congestive heart failure. Am J Dis Child 1986, 140:202-204.
72. Spinnato J.A., Shaver D.C., Flinn G.S., Sibai B.M., Watson D.L., Marin-Garcia J. Fetal supraventricular tachycardia: in utero therapy with digoxin and quinidine. Obstet Gynecol 1984, 64:730-735.
73. Kofinas A.D., Simon N.V., Sagel H., Lyttle E., Smith N., King K. Treatment of fetal supraventricular tachycardia with flecainide acetate after digoxin failure. Am J Obstet Gynecol 1991, 165:630-631.
74. Hunter J., Hirst B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997, 25:129-157.
75. Amano K., Harada Y., Shoda T., Nishijima M., Hiraishi S. Successful treatment of supraventricular tachycardia with flecainide acetate: a case report. Fetal Diagn Ther 1997, 12:328-331.
76. Palmer C.M., Norris M.C. Placental transfer of flecainide. Am J Dis Child 1990, 144:144.
77. Barjot P., Hamel P., Calmelet P., Maragnes P., Herlicoviez M. Flecainide against fetal supraventricular tachycardia complicated by hydrops fetalis. Acta Obstet Gynecol Scand 1998, 77:353-358.
78. Wagner X., Jouglard J., Moulin M., Miller A.M., Petitjean J., Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J 1990, 119:700-702.
79. Bourget P., Pons J.C., Delouis C., Fermont L., Frydman R. Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the third trimester of pregnancy. Ann Pharmacother 1994, 28:1031-1034.
80. O'Hare M.F., Murnaghan G.A., Russell C.J., Leahey W.J., Varma M.P., McDevitt D.G. Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol 1980, 87:814-820.
81. Erkkola R., Lammintausta R., Liukko P., Anttila M. Transfer of propranolol and sotalol across the human placenta. Their effect on maternal and fetal plasma renin activity. Acta Obstet Gynecol Scand 1982, 61:31-34.
82. Hackett L.P., Wojnar-Horton R.E., Dusci L.J., Ilett K.F., Roberts M.J. Excretion of sotalol in breast milk. Br J Clin Pharmacol 1990, 29:277-278.
83. Darwiche A., Vanlieferinghen P., Lemery D., Paire M., Lusson J.R. [Amiodarone and fetal supraventricular tachycardia. Apropos of a case with neonatal hypothyroidism]. Arch Fr Pediatr 1992, 49:729-731.
84. Oudijk M.A., Ruskamp J.M., Ververs F.F., Ambachtsheer E.B., Stoutenbeek P., Visser G.H., et al. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol 2003, 42:765-770.
85. Lisowski L.A., Verheijen P.M., Benatar A.A., Soyeur D.J., Stoutenbeek P., Brenner J.I., et al. Atrial flutter in the perinatal age group: diagnosis, management and outcome. J Am Coll Cardiol 2000, 35:771-777.
86. Oudijk M.A., Michon M.M., Kleinman C.S., Kapusta L., Stoutenbeek P., Visser G.H., et al. Sotalol in the treatment of fetal dysrhythmias. Circulation 2000, 101:2721-2726.
87. Oudijk M.A., Ruskamp J.M., Ambachtsheer B.E., Ververs T.F., Stoutenbeek P., Visser G.H., et al. Drug treatment of fetal tachycardias. Paediatr Drugs 2002, 4:49-63.
88. Ballard P.L., Ballard R.A. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995, 173:254-262.
89. Tsuei S.E., Petersen M.C., Ashley J.J., McBride W.G., Moore R.G. Disposition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clin Pharmacol Ther 1980, 28:88-98.
90. Levitz M., Jansen V., Dancis J. The transfer and metabolism of corticosteroids in the perfused human placenta. Am J Obstet Gynecol 1978, 132:363-366.
91. Dancis J., Jansen V., Levitz M. Placental transfer of steroids: effect of binding to serum albumin and to placenta. Am J Physiol 1980, 238:E208-E213.
92. Smith M.A., Thomford P.J., Mattison D.R., Slikker W. Transport and metabolism of dexamethasone in the dually perfused human placenta. Reprod Toxicol 1988, 2:37-43.
93. DellaTorre M., Hibbard J.U., Jeong H., Fischer J.H. Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. Am J Obstet Gynecol 2010, 203. 254-212.
94. Petersen M.C., Nation R.L., Ashley J.J., McBride W.G. The placental transfer of betamethasone. Eur J Clin Pharmacol 1980, 18:245-247.
95. Anderson A.B., Gennser G., Jeremy J.Y., Ohrlander S., Sayers L., Turnbull A.C. Placental transfer and metabolism of betamethasone in human pregnancy. Obstet Gynecol 1977, 49:471-474.
96. Stark M.J., Wright I.M., Clifton V.L. Sex-specific alterations in placental 11beta-hydroxysteroid dehydrogenase 2 activity and early postnatal clinical course following antenatal betamethasone. Am J Physiol Regul Integr Comp Physiol 2009, 297:R510-R514.
97. Murphy V.E., Fittock R.J., Zarzycki P.K., Delahunty M.M., Smith R., Clifton V.L. Metabolism of synthetic steroids by the human placenta. Placenta 2007, 28:39-46.
98. Stoppa-Vaucher S., Van Vliet G., Deladoey J. Discovery of a fetal goiter on prenatal ultrasound in women treated for Graves' disease: first, do no harm. Thyroid 2011, 21:931-933.
99. Hashimoto H., Hashimoto K., Suehara N. Successful in utero treatment of fetal goitrous hypothyroidism: case report and review of the literature. Fetal Diagn Ther 2006, 21:360-365.
100. Miyata I., Abe-Gotyo N., Tajima A., Yoshikawa H., Teramoto S., Seo M., et al. Successful intrauterine therapy for fetal goitrous hypothyroidism during late gestation. Endocr J 2007, 54:813-817.
101. Ribault V., Castanet M., Bertrand A.M., Guibourdenche J., Vuillard E., Luton D., et al. Experience with intraamniotic thyroxine treatment in nonimmune fetal goitrous hypothyroidism in 12 cases. J Clin Endocrinol Metab 2009, 94:3731-3739.
102. Bussel J.B., Berkowitz R.L., Hung C., Kolb E.A., Wissert M., Primiani A., et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010, 203. 135.e1-e14.
103. Moise K.J. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008, 112:164-176.
104. Davies J., Chant R., Simpson S., Powell R. Routine antenatal anti-D prophylaxis - is the protection adequate?. Transfus Med 2011, 21:421-426.
105. Turner R.M., Lloyd-Jones M., Anumba D.O., Smith G.C., Spiegelhalter D.J., Squires H., et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One 2012, 7:e30711.